These data demonstrate that HDACi-mediated Chk1 downregulation is not drug dependent and class I HDACs are likely mediators of the HDACi effect on Chk1 downregulation in NSCLC cells. The gene discussed is CHEK1; the disease is non-small cell lung carcinoma.